Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ICCC vs ENTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICCC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–3 Matrix Metrics)

ICCC Overall Winner 6-Pillar Tally: ICCC 5 – 1 ENTX Matrix Metrics: ICCC 6 – 3 ENTX

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Entera Bio Ltd. (ENTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas ENTX carries 53.9/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ENTX currently prints a higher short-term Unified Composite Score (53.9/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.2% vs. 0.0% operating margin) and revenue trajectory (+11.5% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ICCC vs ENTX
ICCC NASDAQ Head-to-Head Winner
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.24β · 46% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 68
RSI-14: 67.5 · SMA20: $10.37 · SMA50: $10.13
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
-2.89% 1D
Market Cap $541.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 46% Vol
Unified Composite Score
53.9 / 100 HOLD
Tech 37.0 Fund 54.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.5 · SMA20: $3.09 · SMA50: $2.90

6-Pillar Scorecard Institutional Category Breakdown (ICCC 5 – 1 ENTX)

Columns: Metric · ICCC · ENTX
1. Valuation Multiples ICCC
Forward P/E N/M N/M
Trailing P/E 56.6x N/M
PEG Ratio N/M N/M
EV / Revenue 1.6x N/M
2. Growth & Scale ICCC
Revenue Growth (YoY) +11.5% -100.0%
Earnings Growth (YoY) +259.9% +0.0%
TTM Revenue (USD) $67M N/A
Market Cap $97.7M $541.6M
3. Profitability & Quality ICCC
Gross Margin 40.3% N/A
Operating Margin 15.2% 0.0%
Net Profit Margin 2.6% 0.0%
Return on Equity (ROE) 2.6% -20.3%
4. Balance Sheet & Cash Flow ICCC
Cash Generation (TTM) $7.4M -$16M
Cash Flow Margin 11.0% N/A
Net Cash / Leverage $13M Net Debt (0.44x D/E) $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 113.8% (32nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ICCC
OpEx & R&D Intensity 25.1% of Rev ($17M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ICCC (6) vs ENTX (3)
Institutional Metric ICCC ENTX Criterion Row Edge
Market Capitalization
Scale
$97.7M $541.6M Larger Scale ENTX
Trailing P/E Ratio
Valuation
56.6x N/M Lower Multiple ICCC
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+11.5% -100.0% Higher Growth ICCC
Operating Margin (TTM)
Profitability
15.2% 0.0% Higher Margin ICCC
Net Profit Margin
Profitability
2.6% 0.0% Higher Margin ICCC
Return on Equity (ROE)
Capital Efficiency
2.6% -20.3% Higher ROE ICCC
52-Week Range Position
Momentum
91% ($5–$12) 64% ($1–$4) Stronger Trend ICCC
Beta / 30D Volatility
Risk Regime
0.24β · 46% Vol 1.07β · 46% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 53.9 / 100 (HOLD) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
$67M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
40.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.4M ($13M Net Debt (0.44x D/E)) -$16M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +6.46 pp
ICCC: +6.23% · ENTX: +12.69%
3M Horizon ICCC +12.51 pp
ICCC: +17.01% · ENTX: +4.5%
6M Horizon ENTX +130.29 pp
ICCC: +15.24% · ENTX: +145.53%
1Y Horizon ICCC +78.54 pp
ICCC: +88.76% · ENTX: +10.22%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ICCC Revenue ENTX Revenue ICCC Op. Margin ENTX Op. Margin Margin Leader
FY2018 $10M N/A -13.2% N/A ICCC
FY2019 $10M N/A -7.0% N/A ICCC
FY2020 $20M $0M -9.0% -3059.7% ICCC
FY2021 $20M $0M 1.3% -2139.6% ICCC
FY2022 $20M $0M -12.4% -9714.2% ICCC
FY2023 $20M N/A -32.9% N/A ICCC
FY2024 $30M $0M -6.2% -5295.6% ICCC
FY2025 $30M $0M 6.0% -27450.0% ICCC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ICCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
79d in phase · OBV NEUTRAL
Current IV 113.8%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ICCC Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($17M)
90D Engineering Disclosures 0 Published
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ICCC vs ENTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Entera Bio Ltd. (ENTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas ENTX carries 53.9/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ENTX currently prints a higher short-term Unified Composite Score (53.9/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.2% vs. 0.0% operating margin) and revenue trajectory (+11.5% vs. -100.0% YoY).

ICCC leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ICCC cumulative revenue shifted +200.0% while ENTX shifted N/A. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.

ICCC screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus ENTX (-20.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.